

REMARKS

Claims 1, 3, 5, 179-184, 186, 187, 189, 192, 193, 195, 201, 204-212, 222-227, 231-233, 241, 242, 244, 245, 250, 280-299, 303, and 305-308 are pending in this application. Applicants note with appreciation that claims 1, 5, 179, 181, 183, 184, 186, 187, 189, 192, 193, 195, 201, 204-212, 222-227, 231-233, 241, 242, 244, 245, 250, 280-299, and 303-308 have been allowed. Claims 286 and 287 have been amended to clarify that the claims are directed to a pharmaceutical composition and a kit, respectively. New claims 309-323 have been added to clarify what Applicants regard as the invention. Specifically, new claims 309-319 recite additional specific embodiments of the claimed antibodies and new claims 320-323 recite pharmaceutical compositions, lyophilized formulations, and liquid formulations of said antibodies. Support for the new claims can be found throughout the specification. See, *e.g.*, the Table below.

New Claim	Support in specification
320 (pharmaceutical compositions & routes of administration)	Page 76, lines 32-35; page 83, lines 23-24; and page 86, line 35; Page 84, lines 4-13
321 (sustained release formulations)	Page 85, lines 23-24
322 (lyophilized formulations)	Page 84, lines 32-35
323 (liquid formulations)	Page 85, lines 5-8

Applicants believe that the present claims meet all of the requirements for patentability. Entry and consideration of the foregoing remarks into the file of the subject application is respectfully requested.

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone her at the number provided below.

Respectfully submitted,

Date: November 23, 2005

Margaret B Brivanlou 40,932
For: Margaret B. Brivanlou (Reg. No.)

Jennifer J. Chheda 46,617
By: Jennifer J. Chheda (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6742
(212) 901-9028